The Alnylam Pharmaceuticals, Inc. (ALNY) revenue growth is 23.0%, which is lower than the industry median of 12.6% and the 5-year historical average of 83.0%.
The Alnylam Pharmaceuticals, Inc. (ALNY) operating income growth is (37.3%), compared to the industry median of 10.6% and the 5-year historical average of (16.3%).
The Alnylam Pharmaceuticals, Inc. (ALNY) EPS growth is (38.5%), compared to the industry median of (19.3%) and the 5-year historical average of (14.8%).
The Alnylam Pharmaceuticals, Inc. (ALNY) Free Cash Flow growth is N/A, compared to the industry median of (3.4%) and the 5-year historical average of 10.5%.